Background
==========

Approximately 5% of patients presenting with metastatic cancer develop leptomeningeal carcinomatosis (LC) as an advanced-stage complication of tumor spread to the central nervous system (CNS).[@b1-cmar-11-789],[@b2-cmar-11-789] LC, as defined by the current European Association of Neuro-Oncology--European Society for Medical Oncology guidelines, is a state in which tumor cells have multifocally affected the leptomeninges (pia or arachnoidea) and are frequently observed floating freely within the cerebrospinal fluid (CSF).[@b3-cmar-11-789] Additional parenchymal brain metastases can be identified in 50%--80% of the cases.[@b4-cmar-11-789]--[@b7-cmar-11-789] The incidence of LC varies depending on the primary histology, and it is diagnosed most frequently in patients with breast or lung cancer (10%--35%), as well as melanoma (5%--25%). However, LC diagnosis has become more frequent in gastrointestinal cancers (4%--14%), as well as in cancers of unknown primary (1%--7%).[@b2-cmar-11-789],[@b4-cmar-11-789],[@b8-cmar-11-789],[@b9-cmar-11-789] It is assumed that advances regarding the precision of diagnostic imaging have contributed to the rising overall incidence of LC. The same holds true for the prolonged survival attributable to newly available and efficacious systemic therapies.[@b4-cmar-11-789],[@b8-cmar-11-789],[@b10-cmar-11-789],[@b11-cmar-11-789]

Due to the dismal prognosis of LC, treatment indications and modality are frequently discussed; median overall survival is reported to be in the vicinity of 10--15 weeks.[@b6-cmar-11-789],[@b12-cmar-11-789]--[@b14-cmar-11-789] There have, however, been reports identifying patient subgroups with a favorable outcome and even long-term survival in selected cases.[@b6-cmar-11-789],[@b12-cmar-11-789]--[@b14-cmar-11-789] Among the most decisive factors reported in the literature to influence survival are initial clinical performance, the availability of efficacious systemic treatment options and an aggressive treatment of LC.[@b6-cmar-11-789],[@b13-cmar-11-789]--[@b16-cmar-11-789] The benefit of intrathecal chemotherapy (ITC) has been established in several studies with different regimens based on methotrexate or liposomal cytarabine, among others.[@b17-cmar-11-789]--[@b19-cmar-11-789] An emerging role can be observed for newer small-molecule and targeted drugs such as epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), potentially guided by molecularly informed decisions.[@b20-cmar-11-789]

Radiotherapy (RT) is frequently employed in the form of whole-brain irradiation (WBRT) with a potential survival benefit, especially if additional brain metastases have been diagnosed.[@b14-cmar-11-789],[@b15-cmar-11-789] To achieve symptom palliation and preserve neurologic function, this is often combined with focal RT of symptomatic spinal lesions.[@b14-cmar-11-789]

Craniospinal irradiation (CSI) as a more aggressive and extensive form of RT implies a total or subtotal irradiation of all CNS compartments, including the whole brain and typically complete spine.[@b21-cmar-11-789] It is frequently performed as part of multimodal and curatively intended treatment approaches for pediatric tumors, such as medulloblastomas, or primary CNS tumors with cerebrospinal spread, such as ependymomas.[@b22-cmar-11-789],[@b23-cmar-11-789] For the palliative treatment of metastatic LC, there exists very sparse data supporting CSI, and clinical experience is limited.[@b24-cmar-11-789] Critical consideration has to be given to several clinical as well as technical aspects that make CSI a challenging approach. On the clinical side, dose-limiting toxicity, primarily myelosuppression, can jeopardize the potential benefit and deplete the hematologic reserves needed for subsequent systemic therapy.[@b25-cmar-11-789] On the technical side, field junctions have been necessary to achieve the required vertical radiation field extension, posing dosimetric challenges. However, the use of modern irradiation techniques, such as intensity-modulated radiotherapy (IMRT), helical treatment delivery and proton therapy, has helped overcome some of the obstacles.[@b21-cmar-11-789],[@b26-cmar-11-789]--[@b29-cmar-11-789]

In the sparse body of literature available, it has been reported that in rare cases amounting to 10%--15% of the patients, comparably long-term survival after LC diagnosis could be achieved with the help of decisive treatment.[@b24-cmar-11-789] This report aims to present our institution's experience with the CSI of 25 metastatic patients with LC over a period of 10 years, evaluating the outcome, toxicity and predictive clinical factors to facilitate patient selection.

Patients and methods
====================

We identified 25 patients who received CSI for the treatment of LC at our institution between 2008 and 2018. Patient data were extracted from an oncologic research database maintained at our institution, as well as from the patients' detailed medical records. All reviews were performed following institutional guidelines and the Declaration of Helsinki of 1975 in its most recent version.

Patient characteristics
-----------------------

Median patient age at LC diagnosis was 53 years (IQR: 45--59; min.--max.: 17--74), and median interval from primary diagnosis was 25 months (IQR: 15--85; min.--max.: 0--279). Detailed patient characteristics are illustrated in [Table 1](#t1-cmar-11-789){ref-type="table"}. Primary histology varied: breast cancer was the most frequent (n=15, 60%), followed by lung cancer (n=6, 24%).

For LC diagnosis, all patients received an MRI of the neuroaxis, identifying radiographic evidence of contrast enhancement of the spinal or cerebral meninges.[@b3-cmar-11-789] Histologic confirmation by means of lumbar puncture revealed floating tumor cells in the CSF in 20 cases (80%). The spinal meninges were affected in all presented cases, whereas only eleven patients (44%) showed additional involvement of the intracranial meninges. Additional parenchymal brain metastases were identified in 18 cases (72%). The presence of nodular/bulky disease and CSF flow obstruction were assessed radiologically, as no CSF flow studies were performed.

Symptoms and overall clinical performance (Karnofsky performance scale index \[KPI\]) at the beginning of RT and during follow-up were extracted from the patients' medical records and quantified regarding symptom control, improvement or worsening after therapy. Neurologic function was assessed by an experienced radiation oncologist based on the documented symptoms, and a neurologic function scale (NFS) was used to assess the palliative effect achieved by RT.[@b30-cmar-11-789] Neurologic function was classified as follows: asymptomatic (0), minor neurologic symptoms (1), moderate neurologic symptoms (2), neurologically seriously limited, requiring hospitalization (3) and requiring hospitalization and constant nursing care (4). The outcome of NFS was assessed as either stable, improved or worsened, according to documented symptoms. Symptom control was defined as a constant value of the NFS at therapy completion or first follow-up if available, whereas improvement was defined as a reduction of the NFS by at least 1 point from baseline. Date of death was obtained from medical and official records. Treatment-related toxicity was rated according to the Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0.[@b31-cmar-11-789] Detailed patient characteristics are illustrated in [Table 1](#t1-cmar-11-789){ref-type="table"}.

Treatment planning and delivery
-------------------------------

Treatment indication was discussed interdisciplinarily in the context of our institution's comprehensive cancer center. Patients were selected individually for CSI according to clinically estimated benefit. Selection criteria qualifying for CSI were mild neurologic symptoms, young age, good clinical performance, favorable histology and limited or controlled systemic tumor burden in addition to systemic treatment availability. Patients with poorer clinical performance could receive CSI if they showed multifocally symptomatic spread and symptom improvement by CSI was deemed feasible. Total CSI was performed in 19 patients (76.0%) and subtotal CSI with a maximum total sparing of eight spinal segments in 6 patients (24.0%). Twenty patients (80.0%) received simultaneous CSI, while six patients had previously completed WBRT (sequential CSI). Nine patients had previously received dosimetrically relevant irradiation to parts of the CNS. In those cases, during CSI, the previously irradiated areas were spared or received a lower dose according to the remaining radiotolerance.

Helical IMRT at a TomoTherapy^®^ (Accuray Inc., Sunny-vale, CA, USA) machine was used for CSI. An individual head fixation mask was fitted for each patient. Treatment planning was performed using a 5 mm computed tomography and gadolinium-enhanced magnetic resonance imaging when needed. Dose optimization aimed at a homogeneous dose distribution to all parts of the CNS, including the brain, simultaneously treating additional brain metastases, if existent. No dedicated sparing of intracranial organs at risk (eg, the hippocampus) was performed. All aspects of TomoTherapy planning for CSI have been described earlier.[@b22-cmar-11-789] Five patients received treatment in part at a conventional linear accelerator using laterally opposing fields for cranial irradiation and multi-field three-dimensional conformal radiotherapy for spinal irradiation, as has been previously described.[@b32-cmar-11-789],[@b33-cmar-11-789] Reasons were emergency start of treatment with subsequent TomoTherapy replanning, sequential CSI or subtotal CSI. The most commonly prescribed dose was 36 Gy in 20 fractions. Details on treatment parameters are presented in [Table 2](#t2-cmar-11-789){ref-type="table"}.

Statistical analyses
--------------------

For baseline analyses, descriptive statistics were used. Continuous variables are given as means (SD) and/or median (IQR and range, as appropriate) and categorical variables as absolute and relative frequencies. The median followup time was calculated using the reverse Kaplan--Meier method.[@b34-cmar-11-789] Overall survival (OS) was calculated from the date of LC diagnosis to the last follow-up or death. OS was investigated using the method of Kaplan--Meier. Survival curves for prognostic factors were compared using a two-sided log-rank test. To identify the prognostic factors for OS, univariate and multivariate Cox regression were used. To preserve the validity of multivariate modeling in light of the limited number of patients, a maximum of three covariates that were significant in univariate analysis were chosen for multivariate Cox regression. The covariates thus chosen were the ones most frequently and strongly prognostic in comparable literature, while at the same time being easily and universally assessable in a clinical context. A univariate logistic regression was performed to screen for clinical factors with predictive value regarding symptom response to treatment (NFS stabilization or improvement, according to aforementioned definition). Since this was a retrospective exploratory data analysis, *P*-values are of descriptive nature. A descriptive *P*-value of \<0.05 was considered as statistically significant. Statistical analyses were performed with the software R Version 3.4.3.

Results
=======

Survival and prognostic factors
-------------------------------

Median follow-up, as calculated by the reverse Kaplan--Meier method, was not reached. At the time of analysis, 21 patients had died and 4 patients were still alive. Median OS in all treated patients was 19.3 weeks (IQR: 9.3--34.0). Actuarial follow-up at the time of median OS was 44% ([Figure 1](#f1-cmar-11-789){ref-type="fig"}).

A KPI ≥70% at the beginning of RT was a significant prognostic factor for improved OS with a median OS of 28.3 weeks (IQR: 24.7--56.0) in patients with a good clinical performance (n=15, 60%), whereas patients with poor performance (KPI \<70%, n=10, 40%) showed a median OS of 9.3 weeks (IQR: 7.3--11.7). This prognostic impact was shown in both univariate (HR 0.19, 95% CI: \[0.07, 0.52\], *P*=0.001) and multivariate (HR 0.13, 95% CI: \[0.04, 0.40\], *P*\<0.001) analyses. Similar prognostic value was found for the patients' age at LC diagnosis, with patients ≤55 years of age showing an improved median OS of 28.3 weeks (IQR: 15.7--47.9) in contrast to a median OS of 7.6 weeks (IQR: 5.7--25.7) for older patients. Again, the prognostic value of age confirmed in both univariate (HR 0.30, 95% CI: \[0.11, 0.84\], *P*=0.022) and multivariate (HR 0.21, 95% CI: \[0.06, 0.77\], *P*=0.018) analyses.

Patients initially presenting with mild or moderate symptoms (NFS ≤2) showed an improved OS in univariate analysis (HR 0.20, 95% CI: \[0.06, 0.65\], *P*=0.007). Median OS for these patients was 26.4 weeks (IQR: 11.7--47.9), compared to 9.3 weeks (IQR: 7.6--15.7) for patients presenting with severe neurologic symptoms. Symptom control or improvement in response to CSI was associated with a beneficial effect on OS (median 26.4 weeks, IQR: 15.7--47.9), whereas further neurologic deterioration during and after RT was prognostic for inferior OS (median 7.3 weeks, IQR: 5.7--16.0). The prognostic value of clinical response for improved OS was evident in univariate (HR 0.28, 95% CI: \[0.10, 0.81\], *P*=0.018) and multivariate (HR 0.24, 95% CI: \[0.06, 0.92\], *P*=0.037) analyses. Systemic treatment after CSI completion was administered in a total of nine cases (36.0%), and consisted of chemotherapy in five cases, targeted therapy in three cases and antihormonal therapy in one case. The application of systemic therapy after RT completion was prognostic for improved OS in univariate analysis (HR 0.34, 95% CI: \[0.13, 0.90\], *P*=0.029). The presence of CSF flow obstruction was prognostic of inferior OS (HR 3.02, 95% CI: \[1.14, 7.98\], *P*=0.026), whereas CSF protein levels below 100 mg/dL were prognostic of superior OS in univariate analysis (HR 0.16, 95% CI: \[0.03, 0.73\], *P*=0.018).

Clinical parameters without statistically significant impact on OS in our current analysis were the overall applied biologically equivalent dose and the extent of meningeal spread, involving only the spinal or additionally intracranial meninges. Furthermore, the presence or absence of parenchymal brain metastases, extracerebral metastases, nodular/bulky disease as well as the interval between primary and LC diagnoses showed no significant impact on survival. The clinical factors considered for univariate and multivariate analyses, the corresponding *P*-values and HRs are listed in [Table 3](#t3-cmar-11-789){ref-type="table"}. Age \<55 years at LC diagnosis, KPI ≥70% at LC diagnosis and neurologic response to CSI were considered for multivariate analysis, according to the aforementioned rationale. Kaplan--Meier survival curves stratified by prognostic factors significant in the multivariate analysis are shown in [Figures 2](#f2-cmar-11-789){ref-type="fig"}[](#f3-cmar-11-789){ref-type="fig"}--[4](#f4-cmar-11-789){ref-type="fig"}.

Toxicity and symptom response
-----------------------------

Acute treatment-related toxicity consisted mainly of nausea, fatigue and skin erythema. Those symptoms were mild and became manifest during treatment or within the first 4 weeks from treatment completion. Fatigue and nausea were most common among these symptoms, affecting 21 (84.0%) and 9 (36.0%) patients, respectively. None of these treatment-associated symptoms were considered severe or unexpected, and they were rated grade I or II according to CTCAE v 4.0. Of 25 patients, 20 (80.0%) patients completed the treatment and in 5 cases, treatment was discontinued due to tumor-associated general clinical deterioration. Prophylactic or therapeutic corticosteroids were administered in all patients, and all patients developed complete alopecia in the context of WBRT. Regular blood samples were taken for the early detection of high-grade myelosuppression which was defined as follows: anemia with hemoglobin levels \<8 g/dL, neutropenia with leukocyte levels \<1.0/nL or thrombopenia with thrombocyte levels \<50/nL. Such hematologic toxicity, rated grade III according to CTCAE, was developed by eight patients (32.0%), who required medical intervention under which it was controlled. Six of these patients did not receive any systemic therapy after CSI. As far as can be determined in the context of this retrospective analysis, reasons in all these cases were either general performance related or due to the lack of efficacious medicamentous options. None was directly related to hematologic toxicity. No treatment-associated toxicities of grade IV or V were observed. Details on treatment-related toxicity are given in [Table 4](#t4-cmar-11-789){ref-type="table"}.

According to NFS, the majority of patients (n=19, 76.0%) initially presented with mild to moderate neurologic impairments (NFS 1--2). Severe neurologic impairment (NFS 3--4) was observed in six patients (24.0%). No patient was asymptomatic at the initial presentation. Most common among the documented symptoms were motor and/or sensory deficits (80.0% and 68.0%, respectively), often having led up to LC diagnosis. Headaches and vomiting as a sign of cerebral edema and elevated intracranial pressure (ICP) were frequent in patients presenting with additional brain metastases and were observed in 24.0% (n=6) and 16.0% (n=4) of the patients, respectively. Visual deficits and seizures affected 36.0% (n=9) and 12.0% (n=3) of the patients, respectively.

Regarding the clinical outcome and response to CSI, a stabilization of individual symptoms could be achieved in 44.0%--80.0% of the patients, depending on symptom. ICP-related symptoms were most commonly controlled (76.0%--80.0%) or even improved (16.0%--16.0%) by WBRT. Motor deficits were improved in 36.0% and sensory deficits in 20.0% of the patients. Those symptoms were stabilized in 44.0% and 68.0% of the patients, respectively. However, a fraction of the patients (20.0% for motor deficits and 12.0% for sensory deficits) suffered further symptom deterioration, irrespective of the treatment. Considering overall NFS, symptom palliation in the form of stabilization could be achieved in 40.0% and a sizeable improvement in 28.0% of all patients. Details on symptom response are given in [Table 5](#t5-cmar-11-789){ref-type="table"}.

Positive predictive relevance for symptom response, as determined by the univariate logistic regression, was observed for age ≤55 years (OR 14.00, 95% CI: \[2.13, 138.42\], *P*=0.011), whereas the presence of CSF flow obstruction was a significant negative predictor (OR 0.13, 95% CI: \[0.02, 0.79\], *P*=0.034). A trend toward negative predictive impact was detected for the presence of metastases outside the CNS, but significance was not reached (OR 0.19, 95% CI: \[0.03, 1.07\], *P*=0.069). ORs and the corresponding *P*-values of univariate logistic regression for the endpoint of symptom response are listed in [Table 6](#t6-cmar-11-789){ref-type="table"}.

Discussion
==========

We retrospectively assessed our experience with 25 patients who received CSI as a palliative treatment for LC over a period of 10 years. Overall, from a technical, as well as clinical point of view, treatment was feasible and resulted in OS rates that compare favorably to those described in the literature for this patient collective.[@b13-cmar-11-789],[@b14-cmar-11-789] Acute treatment-related toxicity was moderate and palliative symptom control or improvement was achieved in the majority of patients. Despite the limited number of subjects, we were able to identify age at LC diagnosis, clinical performance and neurologic treatment response as independent prognostic factors for survival, potentially helping in terms of future patient selection.

Regarding the published literature, very little data is available on the subject of CSI for the palliative treatment of LC. To the best of our knowledge, only one other report has specifically evaluated this approach in the past 20 years: Hermann et al reported on their experience treating a total of 16 patients between 1995 and 2000.[@b24-cmar-11-789] They achieved a median OS of 12 weeks and symptom palliation in 68% of the patients. The symptoms that most commonly improved were pain, motor impairments and bladder/bowel incontinence. Reported treatment-related side effects were manageable and included mucositis, nausea and dysphagia. One-third of the patients developed high-grade myelosuppression.[@b24-cmar-11-789]

The current National Comprehensive Cancer Network (NCCN) guidelines recommend CSI for LC only for highly select cases (eg, hematologic malignancies, breast cancer) due to this treatment's toxicity profile.[@b35-cmar-11-789] In general, if the neurologic status and clinical performance are adequate, ITC is the recommended treatment option for non-adherent LC, as stated in the European Association of Neuro-Oncology--European Society for Medical Oncology guidelines.[@b3-cmar-11-789],[@b10-cmar-11-789] Treatment is usually administered via an intraventricular catheter connected to a subcutaneous reservoir (Ommaya reservoir).[@b36-cmar-11-789] Efficacy has been demonstrated for different agents: several randomized trials have established the role of high-dose methotrexate for LC from breast cancer, lymphoma and leukemia,[@b17-cmar-11-789],[@b19-cmar-11-789] as well as the roles of thiotepa and rituximab in hematologic malignancies.[@b17-cmar-11-789],[@b37-cmar-11-789] In breast cancer patients, methotrexate, topotecan, etoposide and trastuzumab were shown to be effective.[@b37-cmar-11-789]--[@b39-cmar-11-789] According to the NCCN guidelines, the administration of RT is recommended mainly to the involved regions in order to achieve symptom palliation, address bulky disease and remove CSF flow obstruction.[@b4-cmar-11-789],[@b35-cmar-11-789]

One of the main obstacles, which in the past limited the feasibility of CSI and resulted in substantial toxicity, was the use of non-conformal, non-image-guided RT techniques. At a conventional linear accelerator, treatment planning for CSI typically included two opposing fields for cranial irradiation and two dorsal fields for spinal irradiation.[@b24-cmar-11-789] To achieve vertical RT field extension, including the entire spine, field junctions were necessary with the associated risk of field overlap or underdosage due to positioning errors. To compensate for those risks, craniocaudal field borders were shifted in regular intervals over the course of RT.[@b24-cmar-11-789] The introduction of TomoTherapy resolved the problem of field junctions, since the continuous movement of the treatment couch during beam administration results in a helical application of the dose, achieving homogeneous dose distributions over a long vertical field extension.[@b40-cmar-11-789],[@b41-cmar-11-789] Combined with the use of IMRT, high-dose conformity can be achieved and dosimetric superiority over conventional RT techniques has been conclusively demonstrated for TomoTherapy in several studies.[@b42-cmar-11-789]--[@b44-cmar-11-789] This allows for the effective sparing of organs at risk, substantially reducing treatment-associated toxicity. Improvements could be achieved regarding the occurrence and severity of mucositis, as well as pulmonary and hematologic toxicity.[@b22-cmar-11-789],[@b45-cmar-11-789],[@b46-cmar-11-789] Regarding hematologic toxicity, however, the wider low-dose distribution of TomoTherapy may, in some cases, result in an increase of red bone marrow exposed to relevant low-dose irradiation (the so-called dose-bath effect).[@b47-cmar-11-789] Modern linear accelerators can perform IMRT employing alternate techniques such as volumetric modulated arc therapy, achieving a similarly favorable reduction of toxicity.[@b48-cmar-11-789] Several comparative studies between Tomo-Therapy and other IMRT techniques have been performed and overall, the resulting dose distributions provide adequate sparing of organs at risk for both techniques.[@b48-cmar-11-789],[@b49-cmar-11-789] Regarding field junctions, different techniques have been conceived to compensate for the positioning errors and avoid relevant over- or underdosage: exploiting the advantages of IMRT, low-gradient junction techniques, as well as non-coplanar IMRT techniques were proven effective dosimetrically.[@b50-cmar-11-789],[@b51-cmar-11-789] Superior sparing of bone marrow in the vertebral bodies, as well as even higher dose conformity can be achieved using proton irradiation.[@b29-cmar-11-789],[@b52-cmar-11-789] Favorable results regarding toxicity and tumor control have been described for proton CSI in pediatric tumors in several recent works, although proton therapy generally reintroduces the issue of field junctions.[@b53-cmar-11-789]--[@b55-cmar-11-789]

Median OS at 19.3 weeks in our current analysis compares favorably to that in previously published analyses in patients with LC: for LC from non-small-cell lung cancer, two relatively large analyses, including 125 and 149 patients, have been published by Morris et al[@b6-cmar-11-789] and Lee et al,[@b13-cmar-11-789] respectively. Median OS estimates were 12.9 and 15.0 weeks in those cohorts that received heterogeneous treatment regimens, including WBRT and RT to the involved regions and differing combinations with ITC and/or systemic chemotherapy. A small subgroup of patients, for whom the administration of EGFR-TKIs was indicated, showed a favorable median OS of up to 14 months.[@b6-cmar-11-789] Similar analyses for breast cancer patients have been recently reviewed by Kak et al.[@b56-cmar-11-789] In several mid-sized cohorts of between 60 and 100 patients, median OS estimates of 10--16 weeks could be achieved.[@b7-cmar-11-789],[@b57-cmar-11-789]--[@b59-cmar-11-789] Therapeutic modalities comprised mostly ITC with methotrexate and second-line thiotepa, although Le Rhun et al described a reasonably sized cohort of 103 patients treated with liposomal cytarabine as a first-line therapy, achieving a median OS of 16.3 weeks.[@b12-cmar-11-789] Overall results for breast cancer are thus comparable to those previously discussed for lung cancer.

A recent publication by Brower et al assessed the outcome of 124 patients with LC from heterogeneous solid tumors, including unfavorable histologies such as small-cell lung-cancer.[@b14-cmar-11-789] In this unselected patient collective, median OS at 9.2 weeks was slightly inferior to the works mentioned before.[@b14-cmar-11-789] In our analysis, no statistical significance could be found for the impact of primary histology and in view of the recently discussed works, this is possibly due to the limited number of patients.

In the published literature, as well as our current analysis, survival seems to be highly dependent on patient selection. This is demonstrated most clearly in clinical performance manifesting itself as a central and consistent prognostic factor throughout the great majority of publications available on the subject of LC.[@b13-cmar-11-789]--[@b16-cmar-11-789],[@b60-cmar-11-789]--[@b62-cmar-11-789] Our analysis is in agreement with that body of literature in confirming the prognostic value of the KPI. For a more comprehensive assessment of the patients' neurologic function, the NFS scale has proven a useful tool with independent prognostic significance. Its key value lies in providing functional quantification to a reasonable extent and summarizing the neurologic symptoms for better comparability. Several recent publications have confirmed the role and applicability of the NFS for the clinical assessment of baseline status and treatment outcome in patients with CNS metastases.[@b30-cmar-11-789],[@b63-cmar-11-789] Age at LC diagnosis was identified as another prognostic factor in our analysis and in this, consistency can be found with the widely established recursive partitioning analysis (RPA) and graded prognostic assessment (GPA) indices for the prognostic evaluation of CNS metastases.[@b64-cmar-11-789]--[@b66-cmar-11-789] The statistically significant identification of these factors despite the limited number of patients in the current analysis emphasizes their decisiveness and suggests that it is, in fact, a very select subgroup of patients that may benefit from CSI as a palliative measure. Furthermore, this implies that rigorous patient selection, based on thorough clinical assessment, and interdisciplinary decision making are necessary to choose the best treatment approach after LC diagnosis.

Limitations of the current study include its retrospective nature and the small number of patients, as well as a possible selection bias, owing to the fact that CSI for the palliative treatment of LC is not an approach generally recommended by the current guidelines. Consequently, it was decided upon on an individual basis for each patient in this group and for differing reasons, including mostly young age, good performance and clinically estimated benefit. Furthermore, the very small number of patients receiving ITC in our cohort permits no assessment of the effect ITC may have had on survival. Analogously, in the era of targeted therapies with proven efficacy inside the CNS,[@b67-cmar-11-789],[@b68-cmar-11-789] comparative data with this form of treatment would be warranted.

Conclusion
==========

To the best of our knowledge, this is the larger of only two cohorts in the current literature, for which the specific effect of CSI in the palliative treatment of LC has been evaluated. We could demonstrate treatment feasibility and potential therapeutic value in carefully selected patients, alleviating preexisting symptoms or delaying neurologic deterioration. OS after CSI was comparable to rates described in the current literature for patients with LC. To achieve a reasonable toxicity profile, the use of modern irradiation techniques, such as helical IMRT, is warranted. Patient selection should be done on an individual basis, taking into account prognostic factors such as age, clinical performance, neurologic function and the availability of systemic treatment options.
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![Overall survival for 25 patients receiving CSI, calculated from the date of LC diagnosis until death or the last follow-up.\
**Abbreviations:** CSI, craniospinal irradiation; LC, leptomeningeal carcinomatosis.](cmar-11-789Fig1){#f1-cmar-11-789}

![Kaplan--Meier survival curves stratified by age at LC diagnosis, *P*=0.015 (two-sided log-rank test).\
**Abbreviation:** LC, leptomeningeal carcinomatosis.](cmar-11-789Fig2){#f2-cmar-11-789}

![Kaplan--Meier survival curves stratified by KPI, *P*\<0.001 (two-sided log-rank test).\
**Abbreviation:** KPI, Karnofsky performance scale index.](cmar-11-789Fig3){#f3-cmar-11-789}

![Kaplan--Meier survival curves stratified by neurologic symptom response, *P*=0.012 (two-sided log-rank test).\
**Note:** NFS 0, asymptomatic; NFS 1--2, mild or moderate neurologic symptoms; NFS 3--4, severe neurologic symptoms, requiring hospitalization.\
**Abbreviation:** NFS, neurologic function scale.](cmar-11-789Fig4){#f4-cmar-11-789}

###### 

Patient characteristics (N=25)

  -------------------------------------------------------------- -------------
  **Age (years)**                                                
   Median                                                        53
   Q1--Q3                                                        45--59
   Min.--max.                                                    17.0--74.0
  **Gender**                                                     
   Female                                                        16 (64.0%)
   Male                                                          9 (36.0%)
  **Primary histology**                                          
   Breast cancer                                                 15 (60.0%)
   Lung cancer                                                   6 (24.0%)
   Gastrointestinal cancers                                      2 (8.0%)
   Myeloid leukemia                                              1 (4.0%)
   Sarcoma                                                       1 (4.0%)
  **Interval from primary diagnosis to LC diagnosis (months)**   
   Median                                                        25
   Q1--Q3                                                        15--85
   Min.--max.                                                    0.0--279.0
  **KPI at LC diagnosis (%**)                                    
   Median                                                        70
   Q1--Q3                                                        60--70
   Min.--max.                                                    30--90
  **Metastases outside CNS**                                     
   Yes                                                           16 (64.0%)
   No                                                            9 (36.0%)
  **Parenchymal brain metastases**                               
   Yes                                                           18 (72.0%)
   No                                                            7 (28.0%)
  **Last therapy before CSI**                                    
   None                                                          11 (44.0%)
   Intrathecal chemotherapy                                      4 (16.0%)
   Targeted therapy                                              3 (12.0%)
   Antihormonal therapy                                          3 (12.0%)
   Systemic chemotherapy                                         3 (12.0%)
   Combination therapy                                           1 (4.0%)
  **Systemic therapy after CSI**                                 
   None                                                          16 (64.0%)
   Systemic chemotherapy                                         5 (20.0%)
   Targeted therapy                                              3 (12.0%)
   Antihormonal therapy                                          1 (4.0%)
  **Diagnostics**                                                
   MRI                                                           25 (100.0%)
   Lumbar puncture                                               20 (80.0%)
   Both                                                          20 (80.0%)
  **LC spread**                                                  
   Spine                                                         25 (100.0%)
   Brain                                                         11 (44.0%)
   Both                                                          11 (44.0%)
  **CSF protein level**                                          
   Mean                                                          384.7
   SD                                                            684.39
   Median                                                        194
   Q1--Q3                                                        99.3--338
   Min.--max.                                                    59.3--3,200
  **Neurologic function (NFS) before treatment**                 
   0                                                             0 (0.0%)
   1                                                             7 (28.0%)
   2                                                             12 (48.0%)
   3                                                             6 (24.0%)
  -------------------------------------------------------------- -------------

**Notes:** NFS 0, asymptomatic; NFS 1--2, mild or moderate neurologic symptoms; NFS 3--4, severe neurologic symptoms, requiring hospitalization. Data shown as n (%) unless indicated otherwise..

**Abbreviations:** CNS, central nervous system; CSI, craniospinal irradiation; KPI, Karnofsky performance scale index; LC, leptomeningeal carcinomatosis; MRI, magnetic resonance imaging; NFS, neurologic function scale.

###### 

Prior radiotherapy and detailed treatment parameters for CSI

  ----------------------------------------------------- ------------
  **Prior radiotherapy outside CNS, n (%)**             
   No                                                   21 (84.0%)
   Yes                                                  4 (16.0%)
  **Prior radiotherapy to parts of the CNS, n (%)**     
   None                                                 16 (64.0%)
   WBRT                                                 5 (20.0%)
   SRS                                                  2 (8.0%)
   WBRT and SRS                                         1 (4.0%)
   Other                                                1 (4.0%)
  **Cumulative physical dose for CSI**                  
   Mean                                                 32.4
   SD                                                   5.96
   Median                                               35.2
   Q1--Q3                                               30.6--36
   Min.--max.                                           14.4--36.0
  **Physical dose per fraction for CSI**                
   Mean                                                 2.0
   SD                                                   0.43
   Median                                               1.8
   Q1--Q3                                               1.8--1.8
   Min.--max.                                           1.6--3.0
  **Number of fractions**                               
   Median                                               20
   Q1--Q3                                               14--20
   Min.--max.                                           8.0--22.0
  **Biologically equivalent cumulative dose for CSI**   
   Mean                                                 38.2
   SD                                                   7.36
   Median                                               40.8
   Q1--Q3                                               39--42.5
   Min.--max.                                           17.0--43.8
  ----------------------------------------------------- ------------

**Note:** BED is calculated with an underlying assumed α*/*β=10 for malignant cells.

**Abbreviations:** BED, biologically equivalent dose; CNS, central nervous system; CSI, craniospinal irradiation; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy.

###### 

Factors analyzed in univariate and multivariate Cox regression with the corresponding HRs and *P*-values

  Factor analyzed                                       HR       95% CI         *P*-value
  ----------------------------------------------------- -------- -------------- -----------
                                                                                
  **Univariate Cox regression**                                                 
  Age ≤55 years at LC diagnosis                         0.298    0.106--0.837   **0.022**
  Male gender                                           0.861    0.340--2.179   0.752
  NFS ≤2 at LC diagnosis                                0.022    0.063--0.649   **0.007**
  KPI ≥70% at LC diagnosis                              0.192    0.071--0.516   **0.001**
  Breast cancer histology                               1.052    0.426--2.599   0.912
  Systemic therapy after CSI completion                 0.337    0.127--0.897   **0.029**
  Involvement of cranial meninges                       0.821    0.338--1.998   0.664
  Tumor cells in CSF                                    0.986    0.322--3.017   0.980
  Parenchymal brain metastases present                  0.957    0.365--2.509   0.929
  Interval between primary diagnosis and LC diagnosis   1.002    0.996--1.008   0.473
  High-grade myelosuppression after CSI                 1.185    0.479--2.934   0.713
  Neurologic response to CSI                            0.284    0.100--0.806   **0.018**
  Metastases outside CNS present                        1.420    0.555--3.630   0.464
  Applied BED                                           0.933    0.865--1.008   0.077
  CSF flow obstruction                                  3.0201   1.143--7.982   0.026
  Nodular/bulky disease                                 1.9299   0.809--4.602   0.138
  CSF protein level \<100 mg/dL                         0.1581   0.034--0.727   0.018
  **Multivariate Cox regression**                                               
  Age ≤55 years at LC diagnosis                         0.213    0.059--0.768   **0.018**
  KPI ≥70% at LC diagnosis                              0.128    0.041--0.400   
  Neurologic response to CSI                            0.235    0.060--0.919   **0.037**

**Note:** Significant *P*-values indicated in bold type.

**Abbreviations:** BED, biologically equivalent dose; CNS, central nervous system; CSF, cerebrospinal fluid; CSI, craniospinal irradiation; KPI, Karnofsky performance scale index; LC, leptomeningeal carcinomatosis; NFS, neurologic function scale.

###### 

Acute treatment-associated toxicity

  Toxicity           n    \%
  ------------------ ---- ------
  Nausea             9    36.0
  Fatigue            21   84.0
  Skin erythema      7    28.0
  Myelosuppression   8    32.0

###### 

Response of individual symptoms and NFS to treatment

                      Before CSI   Clinical outcome after CSI                              
  ------------------- ------------ ---------------------------- --- ------ ---- ------ --- ------
  Headache            19           76.0                         4   16.0   19   76.0   2   8.0
  Vomiting            14           56.0                         4   16.0   20   80.0   1   4.0
  Visual impairment   4            16.0                         4   16.0   18   72.0   3   12.0
  Seizures            3            12.0                         4   16.0   20   80.0   1   4.0
  Motor deficits      20           80.0                         9   36.0   11   44.0   5   20.0
  Sensory deficits    17           68.0                         5   20.0   17   68.0   3   12.0
  NFS 0               0            0.0                          0   0.0    0    0.0    0   0.0
  NFS 1--2            19           76.0                         4   16.0   9    36.0   6   24.0
  NFS 3--4            7            28.0                         3   12.0   1    4.0    2   8.0

**Note:** NFS 0, asymptomatic, NFS 1--2, mild or moderate neurologic symptoms; NFS 3--4, severe neurologic symptoms, requiring hospitalization.

**Abbreviations:** CSI, craniospinal irradiation; NFS, neurologic function scale.

###### 

Factors analyzed in univariate logistic regression for the endpoint of symptom response with the corresponding ORs and *P*-values

  Factor analyzed                              OR       95% CI           *P*-value
  -------------------------------------------- -------- ---------------- -----------
                                                                         
  Age ≤55 years at LC diagnosis                14.000   2.130--138.417   **0.011**
  Male gender                                  0.417    0.069--2.387     0.323
  NFS ≤2 at LC diagnosis                       1.083    0.125--7.359     0.936
  KPI ≥70% at LC diagnosis                     1.833    0.326--10.622    0.486
  Breast cancer histology                      0.250    0.038--1.405     0.125
  Systemic therapy after CSI completion        6.222    0.837--129.893   0.120
  Involvement of cranial meninges              0.327    0.051--1.803     0.209
  Tumor cells in CSF                           0.464    0.022--3.960     0.527
  Parenchymal brain metastases present         1.250    0.197--10.564    0.819
  Interval primary diagnosis to LC diagnosis   0.994    0.983--1.005     0.271
  High-grade myelosuppression after CSI        0.694    0.117--4.429     0.687
  Metastases outside CNS present               0.185    0.026--1.073     0.069
  Applied BED                                  1.213    1.036--1.700     0.082
  CSF flow obstruction                         0.129    0.016--0.792     **0.034**
  Nodular/bulky disease                        0.420    0.067--2.291     0.325
  CSF protein level \<100 mg/dL                1.500    0.212--13.563    0.691

**Note:** Significant *P*-values are indicated in bold type.

**Abbreviations:** BED, biologically equivalent dose; CNS, central nervous system; CSF, cerebrospinal fluid; CSI, craniospinal irradiation; KPI, Karnofsky performance scale index; LC, leptomeningeal carcinomatosis; NFS, neurologic function scale.
